Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 453

1.

Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation.

Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL.

Ther Drug Monit. 2001 Jun;23(3):263-7.

PMID:
11360036
2.

Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.

Olsen GD, Bennett WM, Porter GA.

Clin Pharmacol Ther. 1975 Jun;17(6):677-84.

PMID:
1095281
3.

Prediction of unbound propofol concentrations in a diabetic population.

de la Fuente L, Lukas JC, Jauregizar N, Vázquez JA, Calvo R, Suárez E.

Ther Drug Monit. 2002 Dec;24(6):689-95.

PMID:
12451283
4.

Prednisolone protein binding in renal transplant patients.

Reece PA, Disney AP, Stafford I, Shastry JC.

Br J Clin Pharmacol. 1985 Aug;20(2):159-62.

5.

Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases.

Tiula E, Haapanen EJ, Neuvonen PJ.

Int J Clin Pharmacol Ther Toxicol. 1987 Sep;25(9):469-75.

PMID:
3679617
6.

Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.

Odar-Cederlof I.

Clin Pharmacokinet. 1977 Mar-Apr;2(2):147-53.

PMID:
324689
7.

Serum protein binding kinetics of phenytoin in monotherapy patients.

Kodama H, Kodama Y, Shinozawa S, Kanemaru R, Todaka K, Mitsuyama Y.

J Clin Pharm Ther. 1998 Oct;23(5):361-5.

PMID:
9875684
8.

In vivo binding characteristics of phenytoin to serum proteins in monotherapy for adults with epilepsy.

Kodama H, Kodama Y, Shinozawa S, Kanemaru R, Todaka K, Mitsuyama Y.

Am J Ther. 2000 Nov;7(6):359-63.

PMID:
11304643
9.

A graphical nomogram method for predicting toxic concentrations of unbound phenytoin.

Pospisil J, Pelclová D.

Int J Clin Pharmacol Ther. 1994 Mar;32(3):122-5.

PMID:
8205372
10.
11.

Decreased plasma protein binding of diazoxide in uremia.

O'Malley K, Velasco M, Pruitt A, McNay JL.

Clin Pharmacol Ther. 1975 Jul;18(1):53-8.

PMID:
1149362
12.

[Preoperative prediction of creatinine clearance by using serum creatinine].

Egi A, Fukuda H, Kawamoto M, Yuge O.

Masui. 2004 Nov;53(11):1306-10. Japanese.

PMID:
15587188
13.

Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.

Tiula E, Tallgren LG, Neuvonen PJ.

Int J Clin Pharmacol Ther Toxicol. 1987 Oct;25(10):545-52.

PMID:
3429058
14.

Indirect estimation of the unbound fraction of cyclosporine in plasma.

Akhlaghi F, Ashley JJ, Keogh AM, Brown KF.

Ther Drug Monit. 1998 Jun;20(3):301-8.

PMID:
9631927
16.

Decreased plasma protein binding of phenytoin in patients on valproic acid.

Dahlqvist R, Borgå O, Rane A, Walsh Z, Sjöqvist F.

Br J Clin Pharmacol. 1979 Dec;8(6):547-52.

17.

In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.

Kodama H, Kodama Y, Shinozawa S, Kanemaru R, Itokazu N, Sugimoto T.

Int J Clin Pharmacol Ther. 2000 Jan;38(1):25-9.

PMID:
10667833
18.

Renal function and therapeutic concentrations of phenytoin.

Liponi DF, Winter ME, Tozer TN.

Neurology. 1984 Mar;34(3):395-7.

PMID:
6538287
19.

Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.

Johnson GJ, Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RF.

Br J Clin Pharmacol. 1989 Jun;27(6):843-9.

20.

Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance.

Vormfelde SV, Mück W, Freudenthaler SM, Heyen P, Schmage N, Kuhlmann J, Müller GA, Gundert-Remy UM, Gleiter CH.

J Clin Pharmacol. 1999 Feb;39(2):147-54.

PMID:
11563406

Supplemental Content

Support Center